RU2006144809A - Комбинация органических соединений - Google Patents
Комбинация органических соединений Download PDFInfo
- Publication number
- RU2006144809A RU2006144809A RU2006144809/15A RU2006144809A RU2006144809A RU 2006144809 A RU2006144809 A RU 2006144809A RU 2006144809/15 A RU2006144809/15 A RU 2006144809/15A RU 2006144809 A RU2006144809 A RU 2006144809A RU 2006144809 A RU2006144809 A RU 2006144809A
- Authority
- RU
- Russia
- Prior art keywords
- disease
- rheumatoid arthritis
- arthritis
- treatment
- rapamycin
- Prior art date
Links
- 150000002894 organic compounds Chemical class 0.000 title 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 24
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 20
- 238000011282 treatment Methods 0.000 claims 20
- 206010003246 arthritis Diseases 0.000 claims 16
- 206010012601 diabetes mellitus Diseases 0.000 claims 16
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 12
- 229960002930 sirolimus Drugs 0.000 claims 12
- 201000010099 disease Diseases 0.000 claims 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 11
- 206010019280 Heart failures Diseases 0.000 claims 10
- 208000001647 Renal Insufficiency Diseases 0.000 claims 10
- 208000017169 kidney disease Diseases 0.000 claims 10
- 201000006370 kidney failure Diseases 0.000 claims 10
- 208000024891 symptom Diseases 0.000 claims 10
- 229940124302 mTOR inhibitor Drugs 0.000 claims 9
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims 9
- 206010002383 Angina Pectoris Diseases 0.000 claims 8
- 239000004072 C09CA03 - Valsartan Substances 0.000 claims 7
- 206010020772 Hypertension Diseases 0.000 claims 7
- 239000003937 drug carrier Substances 0.000 claims 7
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 claims 7
- 229960004699 valsartan Drugs 0.000 claims 7
- 206010003658 Atrial Fibrillation Diseases 0.000 claims 6
- 239000000400 angiotensin II type 1 receptor blocker Substances 0.000 claims 6
- 230000002265 prevention Effects 0.000 claims 6
- 230000002792 vascular Effects 0.000 claims 6
- 208000024827 Alzheimer disease Diseases 0.000 claims 5
- 201000001320 Atherosclerosis Diseases 0.000 claims 5
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 5
- 208000028698 Cognitive impairment Diseases 0.000 claims 5
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 5
- 208000010412 Glaucoma Diseases 0.000 claims 5
- 206010018364 Glomerulonephritis Diseases 0.000 claims 5
- 206010049694 Left Ventricular Dysfunction Diseases 0.000 claims 5
- 208000019695 Migraine disease Diseases 0.000 claims 5
- 208000018262 Peripheral vascular disease Diseases 0.000 claims 5
- 208000003782 Raynaud disease Diseases 0.000 claims 5
- 208000012322 Raynaud phenomenon Diseases 0.000 claims 5
- 206010039710 Scleroderma Diseases 0.000 claims 5
- 208000006011 Stroke Diseases 0.000 claims 5
- 206010042600 Supraventricular arrhythmias Diseases 0.000 claims 5
- 206010047281 Ventricular arrhythmia Diseases 0.000 claims 5
- 230000001154 acute effect Effects 0.000 claims 5
- 239000003435 antirheumatic agent Substances 0.000 claims 5
- 230000001684 chronic effect Effects 0.000 claims 5
- 208000010877 cognitive disease Diseases 0.000 claims 5
- 230000006378 damage Effects 0.000 claims 5
- 208000033679 diabetic kidney disease Diseases 0.000 claims 5
- 230000000694 effects Effects 0.000 claims 5
- 230000003628 erosive effect Effects 0.000 claims 5
- 206010061989 glomerulosclerosis Diseases 0.000 claims 5
- 208000019622 heart disease Diseases 0.000 claims 5
- 206010020718 hyperplasia Diseases 0.000 claims 5
- 206010020871 hypertrophic cardiomyopathy Diseases 0.000 claims 5
- 206010027599 migraine Diseases 0.000 claims 5
- 208000010125 myocardial infarction Diseases 0.000 claims 5
- 230000001575 pathological effect Effects 0.000 claims 5
- 230000000750 progressive effect Effects 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 208000037812 secondary pulmonary hypertension Diseases 0.000 claims 5
- 230000006641 stabilisation Effects 0.000 claims 5
- 238000011105 stabilization Methods 0.000 claims 5
- 208000019553 vascular disease Diseases 0.000 claims 5
- 206010003662 Atrial flutter Diseases 0.000 claims 4
- 208000032781 Diabetic cardiomyopathy Diseases 0.000 claims 4
- 208000004248 Familial Primary Pulmonary Hypertension Diseases 0.000 claims 4
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims 4
- 201000008312 primary pulmonary hypertension Diseases 0.000 claims 4
- 201000001474 proteinuria Diseases 0.000 claims 4
- 206010039808 Secondary aldosteronism Diseases 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 208000027032 Renal vascular disease Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000003087 receptor blocking agent Substances 0.000 claims 2
- 208000015670 renal artery disease Diseases 0.000 claims 2
- QFMKPDZCOKCBAQ-NFCVMBANSA-N sar943-nxa Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)CC1 QFMKPDZCOKCBAQ-NFCVMBANSA-N 0.000 claims 2
- PTBDIHRZYDMNKB-UHFFFAOYSA-M 3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate Chemical compound OCC(C)(CO)C([O-])=O PTBDIHRZYDMNKB-UHFFFAOYSA-M 0.000 claims 1
- 241001606201 Patia Species 0.000 claims 1
- 230000003356 anti-rheumatic effect Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000037920 primary disease Diseases 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 125000003831 tetrazolyl group Chemical group 0.000 claims 1
- CGTADGCBEXYWNE-JUKNQOCSSA-N zotarolimus Chemical compound N1([C@H]2CC[C@@H](C[C@@H](C)[C@H]3OC(=O)[C@@H]4CCCCN4C(=O)C(=O)[C@@]4(O)[C@H](C)CC[C@H](O4)C[C@@H](/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C3)OC)C[C@H]2OC)C=NN=N1 CGTADGCBEXYWNE-JUKNQOCSSA-N 0.000 claims 1
- 229950009819 zotarolimus Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57172904P | 2004-05-17 | 2004-05-17 | |
| US60/571,729 | 2004-05-17 | ||
| US60056704P | 2004-08-11 | 2004-08-11 | |
| US60/600,567 | 2004-08-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2006144809A true RU2006144809A (ru) | 2008-06-27 |
Family
ID=35134672
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2006144809/15A RU2006144809A (ru) | 2004-05-17 | 2005-05-13 | Комбинация органических соединений |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20080280939A1 (https=) |
| EP (1) | EP1755681A2 (https=) |
| JP (1) | JP2007538030A (https=) |
| KR (1) | KR20070012486A (https=) |
| AU (1) | AU2005244437A1 (https=) |
| BR (1) | BRPI0511262A (https=) |
| CA (1) | CA2561717A1 (https=) |
| MX (1) | MXPA06013294A (https=) |
| RU (1) | RU2006144809A (https=) |
| WO (1) | WO2005110480A2 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1859274A2 (en) * | 2005-03-07 | 2007-11-28 | Novartis AG | Genes involved in neurodegenerative conditions |
| US20080207671A1 (en) * | 2006-07-31 | 2008-08-28 | The Regents Of The University Of Michigan | Diagnosis and treatment of diseases arising from defects in the tuberous sclerosis pathway |
| AU2007287809A1 (en) * | 2006-08-22 | 2008-02-28 | Novartis Ag | Rapamycin and its derivatives for the treatment of liver-associated fibrosing disorders |
| EP2131821B1 (en) | 2007-03-07 | 2018-05-09 | Abraxis BioScience, LLC | Nanoparticle comprising rapamycin and albumin as anticancer agent |
| US20100166869A1 (en) * | 2007-05-03 | 2010-07-01 | Desai Neil P | Methods and compositions for treating pulmonary hypertension |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0306858A (pt) * | 2002-01-10 | 2004-11-03 | Novartis Ag | Sistemas de liberação de drogas para a prevenção e tratamento de doenças vasculares compreendendo rapamicina e derivados da mesma |
| PT1478648E (pt) * | 2002-02-01 | 2014-07-15 | Ariad Pharma Inc | Compostos contendo fósforo e suas utilizações |
-
2005
- 2005-05-13 BR BRPI0511262-1A patent/BRPI0511262A/pt not_active IP Right Cessation
- 2005-05-13 RU RU2006144809/15A patent/RU2006144809A/ru unknown
- 2005-05-13 AU AU2005244437A patent/AU2005244437A1/en not_active Abandoned
- 2005-05-13 US US11/596,943 patent/US20080280939A1/en not_active Abandoned
- 2005-05-13 MX MXPA06013294A patent/MXPA06013294A/es not_active Application Discontinuation
- 2005-05-13 KR KR1020067023980A patent/KR20070012486A/ko not_active Withdrawn
- 2005-05-13 EP EP05744586A patent/EP1755681A2/en not_active Withdrawn
- 2005-05-13 CA CA002561717A patent/CA2561717A1/en not_active Abandoned
- 2005-05-13 WO PCT/EP2005/005286 patent/WO2005110480A2/en not_active Ceased
- 2005-05-13 JP JP2007517056A patent/JP2007538030A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CA2561717A1 (en) | 2005-11-24 |
| KR20070012486A (ko) | 2007-01-25 |
| WO2005110480A3 (en) | 2006-07-27 |
| AU2005244437A1 (en) | 2005-11-24 |
| EP1755681A2 (en) | 2007-02-28 |
| US20080280939A1 (en) | 2008-11-13 |
| BRPI0511262A (pt) | 2007-11-27 |
| MXPA06013294A (es) | 2007-02-02 |
| WO2005110480A2 (en) | 2005-11-24 |
| JP2007538030A (ja) | 2007-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2007106708A3 (en) | Combinations of the angiotensin ii antagonist valsartan and the nep inhibitor daglutril | |
| Savelieva et al. | Anti-arrhythmic drug therapy for atrial fibrillation: current anti-arrhythmic drugs, investigational agents, and innovative approaches | |
| JP2010280708A5 (https=) | ||
| ATE370732T1 (de) | Pharmazeutische zusammensetzung enthaltend valsartan und nep-inhibitoren | |
| EP3038654B1 (en) | New use | |
| JP2010536761A5 (https=) | ||
| EP2322174A3 (en) | Combined use of valsartan and calcium channel blockers for therapeutic purposes | |
| US20090318530A1 (en) | Pharmaceutical compositions comprising nk1 receptor antagonists and sodium channel blockers | |
| ATE338549T1 (de) | Therapeutische zusammensetzung von amlodipin und benazepril / benazeprilat | |
| KR20090102867A (ko) | Ｎｋ1 수용체 길항제 및 나트륨 채널 차단제를 포함하는 제약 조성물 | |
| CA2735653A1 (en) | Method of treating atrial fibrillation | |
| US20160113937A1 (en) | Discovery of fda-approved drugs as inhibitors of fatty acid binding protein 4 using molecular docking screening | |
| RU2006144809A (ru) | Комбинация органических соединений | |
| WO2014049515A1 (en) | Pyrrolidine substituted flavones for treatment of renal cystic diseases | |
| US20100136024A1 (en) | Selective Inhibition of Histone Deacetylase 6 for Ocular Neuroprotection or for Treatment or Control of Glaucoma | |
| Safar et al. | Thiazide-like/calcium channel blocker agents: a major combination for hypertension management | |
| RU2491934C2 (ru) | Лечение фиброзирующих нарушений | |
| JP2005505605A (ja) | 前痴呆状態におけるロスバスタチン | |
| CN1681533A (zh) | 用于治疗动脉硬化的药用组合物 | |
| CZ378597A3 (cs) | Použití derivátů pyrrolidinu k léčení alkoholismu | |
| BR0317384A (pt) | Combinações de valsartan com inibidores de cox-2 | |
| WO2014061827A1 (en) | Treatment of pulmonary fibrosis using an inhibitor of cbp/catenin | |
| EP4525857A1 (en) | Methods of treating focal segmental glomerulosclerosis with atrasentan | |
| WO2016162886A1 (en) | Hcqs for prophylaxis and treatment of statin induced diabetes | |
| JP2013526499A (ja) | キサンチンオキシダーゼ阻害剤およびスタチンの合剤およびその使用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA91 | Application withdrawn (on applicant's request) |
Effective date: 20090707 |